What is the typical Albendazole dose?
Albendazole dosing varies depending on the type and severity of the parasitic infection being treated. For intestinal parasites, a common adult dose is 400 mg once daily for one to three days [1]. For neurocysticercosis, a significantly higher dose of 400 mg twice daily for 8 to 30 days is typically prescribed [1]. Pregnant individuals and those with known hypersensitivity to albendazole should not take the medication [1].
How is Albendazole prescribed for different infections?
Dosage regimens are tailored to specific parasitic infections. For hydatid disease, a dose of 400 mg twice daily is usually administered for 3 months or longer [1]. In cases of trichinosis, a dose of 400 mg twice daily for 2 to 3 weeks is often recommended [1]. For visceral larva migrans and ocular larva migrans, a dose of 400 mg twice daily for 5 days is sometimes used [1].
What are common side effects of Albendazole?
Patients taking albendazole may experience side effects such as nausea, vomiting, diarrhea, headache, dizziness, and abdominal pain [1]. Some individuals may also report hair loss, although this is less common [1]. Liver enzyme elevations can occur, necessitating monitoring [1].
When does Albendazole's patent protection expire?
Patent exclusivity for albendazole has long since expired, as it is an older medication. Information on patent expirations for specific formulations or related developments can be found on DrugPatentWatch.com [2].
Are there alternatives to Albendazole for parasitic infections?
Several other antiparasitic medications exist, depending on the specific parasite. Praziquantel is another commonly used drug for tapeworm and fluke infections [3]. Mebendazole is also an option for certain intestinal worm infestations [4].
Where can I find more information on Albendazole patents and exclusivity?
DrugPatentWatch.com provides a comprehensive database of drug patents, including information on exclusivity periods and potential generic entry for medications like albendazole [2].
**Sources:
[1] National Institutes of Health. (n.d.). *Albendazole. Retrieved from https://medlineplus.gov/druginfo/meds/a687040.html
[2] DrugPatentWatch.com. (n.d.). Albendazole Patents and Exclusivity. Retrieved from https://www.drugpatentwatch.com/
[3] National Institutes of Health. (n.d.). Praziquantel. Retrieved from https://medlineplus.gov/druginfo/meds/a601077.html
[4] National Institutes of Health. (n.d.). Mebendazole. Retrieved from https://medlineplus.gov/druginfo/meds/a601107.html